Caldecrin proform requires trypsin activation for the acquisition of serum calcium‐decreasing activity

FEBS Letters

Saheki, Takeyori¹  Nishii, Yasuho³  Noikura, Takenori²  Tomomura, Mineko¹  Tomomura, Akito¹  Fukushige, Tomoko¹ 

[1] Department of Biochemistry, Faculty of Medicine, Kagaoshima 890, Japan;Department of Dental Radiology, Dental School, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima 890, Japan;Chugai Pharmaceutical Company, Kyobashi 2-14-1, Chuoku, Tokyo 104, Japan

关键词: Chymotrypsin;    Calcium;    Proform;    caldecrin;    serum calcium-decreasing factor;    DFP;    diisopropyl fluorophosphate;    PMSF;    phenylmethylsulphonyl fluoride;    APMSF;    (4-amidino-phenyl)methane-sulphonyl fluoride;    Suc-Ala-Ala-Pro-Phe-pNA.succinyl-l-alanyl-l-alanyl-l-prolyl-l-phenylalanine p-nitroanilide;   

DOI  :  10.1016/0014-5793(93)80732-A

学科分类：生物化学/生物物理

来源: John Wiley & Sons Ltd.

【 摘 要 】

Proform serum calcium-decreasing factor (procaldecrin) was purified from porcine pancreas acetone powder. Procaldecrin showed chymotrypsin activity after trypsin treatment in a time- and dose-dependent manner. Procaldecrin did not possess serum calcium-decreasing activity but acquired serum calcium-decreasing activity as well as protease activity after trypsin treatment. However, PMSP treatment after activation of procaldecrin by trypsin did not affect the serum calcium-decreasing activity, even though protease activity was nullified by treatment with PMSF. These findings suggest that the serum calcium-decreasing activity acquired by procaldecrin requires confonnational change caused by trypsin treatment.

【 授权许可】

Unknown